Introduction {#sec1}
============

The prevalence of type 2 diabetes and its complications is a global problem. Caucasian and Asian patients with diabetes have an approximately two-fold increased risk of mortality compared with healthy individuals.[@bib1] Therefore, in Asian countries where the prevalence of obesity are rapidly increasing,[@bib2] significant increases in the rate of death from diabetes require urgent attention.

Diabetes contributes to death caused by arterial sclerotic disease[@bib3] and cancer.[@bib4] Stroke, acute myocardial infarction (MI) and chronic kidney disease represent major complications of American patients with diabetes.[@bib5] In European and North American countries, patients with diabetes are at a higher risk of death caused by vascular disease, followed by cancer and other causes.[@bib4] Cancer and diabetes cause each other,[@bib6] and middle-aged to aged patients with diabetes may likely have experienced cancer.[@bib7] Furthermore, renal disease, often accompanying artery calcification, leads to cardiovascular mortality,[@bib8] and in patients with diabetes, renal comorbidity is a significant risk factor for death.[@bib9] Chronic obstructive pulmonary disease, usually caused by cigarette smoking, also frequently accompanies diabetes and leads to high mortality.[@bib10]

Improvements in the treatment of vascular diseases, cancer and chronic kidney and respiratory diseases should be preventing deaths directly caused by diabetes, indicating that the survival of patients with diabetes will increase. However, to our knowledge, no data are currently available in Asian countries that associate the mortality of diabetic patients with comorbidities. This study aimed to determine the contributions of comorbidities and cardiovascular risk factors to the risk of death in Japanese patients with diabetes. For this purpose, we also compared the survival curves of patients with diabetes with or without major comorbidities.

Methods {#sec2}
=======

Participants {#sec2.1}
------------

Between fiscal years 2003 and 2007, the BioBank Japan Project registered 200,000 patients with 47 diseases treated at 12 institutions.[@bib11] The study profiles are published elsewhere.[@bib12], [@bib13], [@bib14] The project follows 39,697 patients with diabetes treated at 66 hospitals. We collected serum samples and information from patients\' medical records. We also collected annual information on survival, mortality and causes of death from patients\' medical records, the residence registry and the Vital Statistics Act.[@bib15] The ages of participants were mainly ≥19 years.

To assess the influence of comorbidities and cardiovascular risk factors on mortality of patients with type 2 diabetes, we eliminated the data of those with diabetes other than type 2 (other endocrinological or metabolic diseases, systemic infectious diseases, other cardiac diseases for the use of steroid and amyotrophic lateral sclerosis).[@bib16] In other words, we did not analyse those with mitochondrial diabetes, maturity-onset diabetes of the young (MODY), hyper- or hypo-thyroidism, Hashimoto\'s thyroiditis, pheochromocytoma, Cushing disease or syndrome, acromegaly, amyloidosis, tuberculosis, atypical mycobacteriosis, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, malignant rheumatoid arthritis, dermatomyositis, polymyositis, systemic sclerosis, steroid use, myocarditis, dilated cardiomyopathy or hypertrophic cardiomyopathy.

Measurements {#sec2.2}
------------

We identified the comorbidities as follows: 1. History of macrovascular disease included acute myocardial infarction, stable or unstable angina pectoris, heart failure, cerebral infarction, cerebral haemorrhage, subarachnoid haemorrhage, cerebral arterial aneurysm, aortic aneurysm and peripheral artery disease (arteriosclerosis obliterans). 2. In the present study, comorbid chronic kidney disease was defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m^2^ at registration, although the guideline for clinical practice require this low level that persists continuously for ≥3 months.[@bib17] Furthermore, stage-3 diabetic nephropathy (overt nephropathy, macroalbuminuria ≥300 mg/g Cr or persistent proteinuria ≥0.5 g/g Cr), stage 4 (kidney failure, eGFR \<30 mL/min/1.73 m^2^) or stage 5 (any status of continued dialysis therapy) were included as comorbid chronic kidney disease.[@bib18] 3. History of chronic respiratory disease included asthma, chronic obstructive pulmonary disease, interstitial pneumonia, pulmonary fibrosis and pneumoconiosis. 4. History of cancer included that of any organ. Serum glycated haemoglobin A1c (HbA1c) levels measured in the scale of The Japanese Diabetes Society (JDS) between 2003 and 2007 years were converted to those in the National Glycohemoglobin Standardization Program (NGSP) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).[@bib19], [@bib20]

Statistical analysis {#sec2.3}
--------------------

We analysed the data to determine the distributions of sex, HbA1c levels, fasting plasma glucose and diabetic complications. We presented the mean (standard deviation \[SD\]) values of age, HbA1c, body mass index (BMI), blood pressure and plasma cholesterol levels and the median (interquartile range) of the follow-up period. For primary outcomes, we used the Cox proportional hazard model[@bib21] to calculate crude and multivariable-adjusted hazard ratios (HRs) in the model with explanatory variables of sex, age, serum HbA1c levels, systolic blood pressure (SBP), serum low-density lipoprotein cholesterol levels, histories of macrovascular disease, chronic respiratory disease and cancer, comorbid chronic kidney disease and smoking status. No multicollinearities were detected in terms of variance inflation factors \< 1.5[@bib22] among the explanatory variables of the multivariate analysis. We depicted Kaplan--Meier estimates for survival curves[@bib23] to analyse the associations of sex, histories of macrovascular disease, chronic respiratory disease and cancer, comorbid chronic kidney disease and smoking status. We used the log-rank test[@bib24] to assess the significance of the differences between survival curves. The statistical analyses were performed using SAS statistical software (version 9.3, SAS Institute, Cary, NC, USA). R statistical software (version 2.15.3, R Project for Statistical Computing, Vienna, Austria) was used to generate Kaplan--Meier estimates. All reported p values were 2-sided, and p \< 0.05 indicates a significant difference.

Ethical considerations {#sec2.4}
----------------------

The ethics committees of the Institute of Medical Science, The University of Tokyo, RIKEN Center for Integrative Medical Sciences and 12 cooperating medical institutions approved the protocol of this study in accordance with the ethical guidelines and regulations of the Declaration of Helsinki. The Japanese guidelines permit the use of data from medical examinations and information without consent if the data are anonymous. Hence, informed consent was not required for the present investigation.

Results {#sec3}
=======

Patients {#sec3.1}
--------

The study comprised 19,830 men (age range, 19--95 years) and 11,004 women (age range, 20--98 years) with type 2 diabetes. [Table 1](#tbl1){ref-type="table"} presents the means (SDs) of age, BMI, HbA1c, blood pressure and the distributions of smoking and drinking status, glycaemic control, macro- and microvascular complications, histories of cancer and respiratory disease, comorbid chronic kidney disease at the baseline and follow-up period. The mean serum HbA1c levels were 7.4% (SD, 1.4) and 57.1 mmol/mol (SD, 15.4) for men and 7.5% (SD, 1.4) and 58.8 mmol/mol (SD, 15.5) for women. The mean ages of men and women were early sixties with mean BMIs of 24--25. At the baseline, 36.9% of men and 35.3% of women had HbA1c \<6.0% (42 mmol/mol), and 61.5%, and 56.6% of the men and women, respectively, had complication of macro- or microvascular diseases.

Association of patients\' characteristics and survival {#sec3.2}
------------------------------------------------------

[Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}, [Fig. 4](#fig4){ref-type="fig"}, [Fig. 5](#fig5){ref-type="fig"}, [Fig. 6](#fig6){ref-type="fig"} present estimated survival curves according to sex, histories of macrovascular disease, chronic respiratory disease and cancer and comorbidities of chronic kidney disease and smoking status. The median survival was short for those with a history of smoking, macrovascular disease, chronic respiratory disease or cancer or comorbidity of chronic kidney disease compared with those without the comorbidities. [Table 2](#tbl2){ref-type="table"} presents crude and adjusted HRs of the explanatory variables associated with mortality. A 10-year incremental increase in age was related to mortality with an adjusted HR = 2.01 (95% confidence interval \[95% CI\], 1.78--2.26). An HbA1c level = 1% and 10 mm Hg systolic blood pressure were significantly related to mortality (adjusted HRs = 1.11 \[95% CI, 1.03--1.19\] and 1.11 \[95% CI, 1.05--1.18\], respectively). The adjusted HRs of patients with histories of macrovascular disease, cancer and chronic respiratory disease and comorbid chronic kidney disease, respectively, were as follows: 1.77 (95% CI, 1.42--2.22), 1.16 (95% CI, 0.86--1.56), 1.58 (95% CI, 1.08--2.31) and 2.03 (95% CI, 1.67--2.47).

Discussion {#sec4}
==========

Here we show that comorbid chronic kidney disease had the most significant influence on survival of patients with type 2 diabetes, followed by a history of macrovascular disease and cigarette smoking. The estimated survival curves show the excess risks of mortality associated with comorbidities of interest.

Interpretations in the context of previous studies {#sec4.1}
--------------------------------------------------

The present data illuminate the excess risk of death of patients with diabetes associated with sex, age, various comorbidities and smoking (current or in the past). The results agree with those of a previous study in North America,[@bib25] indicating that for patients with diabetes, chronic kidney disease confers the highest risk of death among the risk factors listed in [Table 2](#tbl2){ref-type="table"}. Moreover, from literature, a lower glomerular filtration rate (GFR) contributes to a higher rate of all-cause mortality.[@bib26] The relatively low risk of death (HR = 1.16 \[95% CI, 0.86--1.56\]) of patients with a history of cancer may be explained by survivor bias[@bib27] and the use of biguanide metformin. Patients at the onset of cancer ought to have a high risk of mortality. A subset of the studied patients with a history of cancer may have survived from cancer and, at the baseline, may have a lower risk of cancer mortality. Additionally, a Danish study reports a reduced HR of 0.43 (95% CI, 0.23--0.80) for cancer mortality in patients with type 2 diabetes who were treated with biguanide metformin.[@bib28] The agent may be reportedly anti-cancerous by decreased insulin-stimulated proliferation[@bib29] and might decrease mortality risk in the present patients with a history of cancer.

Surprisingly, in appearance, chronic respiratory disease did not largely influence on the natural history of mortality ([Fig. 3](#fig3){ref-type="fig"}). This observation is because the patients were considered survivors from long disease duration of chronic respiratory disease, and patients with severe respiratory disease should have died at the baseline (survivor bias).[@bib27] The risk of Japanese patients with respiratory disease should be determined using prospective cohort data for patients starting from the onset of chronic respiratory disease. Overall, we need to interpret that survivor bias should attenuate the differences as outcomes between patients with and without each comorbidity. In addition, because we preliminarily excluded the influence of steroid use, the adjusted HRs in [Table 2](#tbl2){ref-type="table"} could be attenuated with the data of patients without severe chronic respiratory disease.

A history of macrovascular disease represented a large excess risk of death for 1.77 HR (95% CI, 1.42--2.22). This result is consistent with the results for American patients with adjusted HRs of 1.5 (95% CI, 1.1--2.0), 1.7 (95% CI, 1.2--2.3) and 2.4 (95% CI, 1.7--3.4) for nondiabetic previous MI, diabetic-first MI and diabetic previous MI groups, respectively, as compared with nondiabetic participants with no previous MI.[@bib30] The significantly higher HR should alert patients to adhere to treatment prescribed by a physician and self-treatment. Male sex and age at baseline, unmodifiable risk factors, also exhibited excess mortality risk upon the patients in our data. The United Kingdom Prospective Diabetes Study (UKPDS), including a 4-year follow-up, reports 13% and 11% relative-risk increases in mortality associated with a 1% increase in serum HbA1c levels and a 10-mm Hg increase in SBP, respectively.[@bib31] These data agree with ours as follows: median 8--9 year follow-up with 11% and 11% excess HR associated with a 1% increase in serum HbA1c levels and 10-mm Hg increase in SBP, respectively ([Table 2](#tbl2){ref-type="table"}).

The impacts of current and former smoking on survival curve are different than those on adjusted HR for mortality ([Fig. 6](#fig6){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). For this discrepancy, we consider that patients with serious comorbidities and at high risk of death who must have stopped smoking cigarettes to improve their chances for survival were included in the ex-smoker group at the baseline, and the patients who 'could' continue to smoke represented a lower mortality risk in the crude survival curve. This observation and inference suggests that smoking cessation would extend life expectancy of patients with diabetes. In contrast, when adjusted for all the other risks, the higher HRs of current smokers compared with ex-smokers are medically reasonable. In the United States, approximately 17% of deaths can be attributed to current smoking in the general population.[@bib32] The 1.74 HR (95% CI, 1.30--2.31) of current smokers among Japanese patients with diabetes should not be overlooked, and clinicians should firmly encourage patients to stop smoking because it is a modifiable risk factor.

Practical implications {#sec4.2}
----------------------

Kidney disease accelerates atherosclerosis and therefore increases mortality,[@bib33] contributing to the shorter survival of patients with diabetic nephropathy. A nationwide survey conducted in Japan demonstrates that lower eGFR levels and higher albuminuria linearly increased the incidence of cardiovascular events.[@bib34] Conversely, a reduction in microalbuminuria in Japanese patients with diabetes reportedly results in a reduced cardiovascular risk.[@bib35] The high HR with chronic kidney disease in our data should encourage diabetic patients to preserve renal function.

Cigarette smoking increases the mortality risk of patients with diabetes.[@bib36] A randomised trial demonstrates that cessation of smoking decreases mortality in a general population.[@bib37] The high HR for current smokers in the present study encourages patients with diabetes to stop smoking for longer survival expectancy. We believe that our data reported here that quantify mortality associated with comorbidities of patients with diabetes will be useful for clinicians to determine the priorities of treatments. In particular, we warn current smokers that this modifiable habit will impose approximately the same excess risk of death as 10-year increment of age and a history of macrovascular, chronic respiratory and chronic kidney diseases. Therefore, current smoking virtually ages patients by ten years, thus shortening life expectancy.

Limitations and strengths {#sec4.3}
-------------------------

We introduce here several aspects that strengthen the results. First, physicians diagnosed all diseases included in the BioBank Japan Project, providing internal validation. Second, \>30,000 of the analysed patients with diabetes represent one of the highest numbers among the studied populations of East Asian countries. Third, the availability of detailed medical information allowed us to analyse various comorbidities together.

We note several limitations that may influence generalising the results to clinical practice. The primary limitation is that patients were enrolled during mid-course of disease, and therefore, they were not observed from onset of diabetes. Hence, the disease duration and the therapeutic regimens of the patients may have varied before enrolment. Although multivariable adjustment of the baseline age should attenuate this bias, the estimated survival curves and HRs should be carefully interpreted. Next, the chronological order of onsets of diabetes and comorbidities were unknown. This limitation resulted in the impossibility of causal inference linking comorbidities for exposure and death for outcome. In other words, we could not design the study to answer to the question of whether prevention of diabetic vascular comorbidities reduces the mortality. Third, the registration of diabetic patients in medium-to-large hospitals may have biased diabetes cases toward those of moderate to severe status, and the data may not represent Japanese patients with diabetes. Therefore, comparisons of mortality risks of patients with mild diabetes in primary care clinics are required to validate the data. Another limitation is the follow-up of a median 8--9 years. Because the effects of uncontrolled serum glucose and lipid levels and blood pressure[@bib38] on mortality would accelerate with time,[@bib39] relatively fewer death events during the follow-up period may present smaller HRs. Last, analyses with more detailed information on variables such as diet, physical activity and socioeconomic status, should be considered as well.

Conclusions {#sec5}
===========

Comorbid chronic kidney disease has exhibited the highest risk of mortality risk, followed by macrovascular disease, current smoking and chronic respiratory disease in patients with type 2 diabetes. The results indicate that patients with diabetes should preserve their renal, macrovascular and respiratory functions and terminate cigarette smoking, thus expecting better prognosis on their survival.
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###### 

Baseline characteristics of patients with type 2 diabetic in Biobank Japan cohort.

Table 1

  Characteristics                                                       Men                         Women
  --------------------------------------------------------------------- --------------------------- ---------------------------
  Number (%)                                                            19,830 (64.3)               11,004 (35.7)
  Age, years                                                            63.4 (11.0)                 64.3 (11.2)
  Body mass index, kg/m^2^                                              24.1 (3.7)                  24.7 (4.4)
  Glycated haemoglobin A1c, % and mmol/mol                              7.4 (1.4) and 57.1 (15.4)   7.5 (1.4) and 58.8 (15.5)
  Systolic blood pressure, mm Hg                                        133.6 (17.2)                135.0 (17.6)
  Diastolic blood pressure, mm Hg                                       77.5 (10.9)                 75.6 (10.9)
  Smoking, never/ex-/current, no.                                       5038/8282/6510              8832/990/1182
  Currently drinking, no. (%)                                           10,057 (52.5)               1530 (14.3)
  **Glycated haemoglobin, no. (%)**                                                                 
  \<6.0% (\<42 mmol/mol)                                                7314 (36.9)                 3879 (35.3)
  6.0--6.4% (42--47 mmol/mol)                                           2304 (11.6)                 1097 (10.0)
  6.5--6.9% (48--52 mmol/mol)                                           2842 (14.3)                 1556 (14.1)
  7.0--7.9% (53--63 mmol/mol)                                           3804 (19.2)                 2235 (20.3)
  8.0--8.9% (64--74 mmol/mol)                                           2018 (10.2)                 1230 (11.2)
  ≥9.0% (≥75 mmol/mol)                                                  1548 (7.8)                  1007 (9.2)
  **Fasting plasma glucose, no. (%)**                                                               
  \<126 mg/dL (\<7.0 mmol/L)                                            1136 (10.4)                 763 (12.3)
  ≥126 mg/dL (≥7.0 mmol/L)                                              9829 (89.6)                 5430 (87.7)
  **Vascular complications, no. (%)**                                                               
  None                                                                  7638 (38.5)                 4778 (43.4)
  Macrovascular disease                                                 7368 (37.2)                 3152 (28.6)
  Nephropathy                                                           1039 (5.2)                  578 (5.3)
  Retinopathy                                                           1550 (7.8)                  1090 (9.9)
  Neuropathy                                                            2235 (11.3)                 1406 (12.8)
  **Comorbidity and past histories, no. (%)**                                                       
  Chronic kidney disease                                                6236 (31.5)                 3588 (32.6)
  History of cancer                                                     1910 (9.6)                  949 (8.6)
  History of chronic respiratory disease                                805 (4.1)                   568 (5.2)
                                                                                                    
  Follow-up period from baseline, years, median (interquartile range)   8.03 (5.84--9.67)           8.30 (6.47--9.88)

The data are presented as mean (SD) or number (%) unless stated otherwise.

###### 

Hazard ratios (95% confidence intervals) of risk factors for mortality of patients with type 2 diabetes.

Table 2

  Risk factors                             Crude analysis[a](#tbl2fna){ref-type="table-fn"}   p value       Multivariable analysis[a](#tbl2fna){ref-type="table-fn"}   p value
  ---------------------------------------- -------------------------------------------------- ------------- ---------------------------------------------------------- -------------
  Sex, men                                 1.40 (1.33--1.47)                                  p \< 0.0001   1.39 (1.09--1.78)                                          p = 0.0081
  Age per 10 years                         1.97 (1.92--2.02)                                  p \< 0.0001   2.01 (1.78--2.26)                                          p \< 0.0001
  HbA1c per 1%                             0.97 (0.95--0.99)                                  p = 0.071     1.11 (1.03--1.19)                                          p = 0.0063
  Systolic hypertension per 10 mm Hg       1.06 (1.04--1.07)                                  p \< 0.0001   1.11 (1.05--1.18)                                          p = 0.0002
  Low-density lipoprotein per 10 mg/dL     0.96 (0.94--0.98)                                  p = 0.0005    0.98 (0.95--1.01)                                          p = 0.14
  History of macrovascular disease         1.92 (1.83--2.01)                                  p \< 0.0001   1.77 (1.42--2.22)                                          p \< 0.0001
  History of cancer                        2.48 (2.33--2.64)                                  p \< 0.0001   1.16 (0.86--1.56)                                          p = 0.35
  History of chronic respiratory disease   1.34 (1.21--1.48)                                  p \< 0.0001   1.58 (1.08--2.31)                                          p = 0.019
  Chronic kidney disease                   2.48 (2.36--2.59)                                  p \< 0.0001   2.03 (1.67--2.47)                                          p \< 0.0001
  Non-smoker                               Ref                                                              Ref                                                        
  Ex-smoker                                1.42 (1.35--1.50)                                  p \< 0.0001   1.24 (0.97--1.59)                                          p = 0.081
  Current smoker                           1.20 (1.13--1.28)                                  p \< 0.0001   1.74 (1.30--2.31)                                          p = 0.0002

Hazard ratios were estimated in crude or multivariable Cox proportional hazard model. In the multivariable analysis, no multicollinearity was detected in terms of variance inflation factors \< 1.5.[@bib22]

[^1]: BioBank Japan Cooperative Hospital Group are listed in [Appendix](#appsec1){ref-type="sec"}.
